医院患者高敏心肌肌钙蛋白的真实第99百分位:前瞻性观察性队列研究
该前瞻性观察性队列研究在一家大型教学医院连续纳入20000例因任何临床原因接受血液检查的住院和门诊患者,检测高敏心肌肌钙蛋白I(hs-cTnI)并分析其分布及第99百分位。全人群第99百分位为296 ng/L,而厂商推荐正常上限为40 ng/L;5.4%(n=1080)超过40 ng/L。排除急性心肌梗死(n=122)和因临床原因申请检测者(n=1707)后,剩余18171例第99百分位为189 ng/L;住院患者第99百分位563 ng/L(n=4759),门诊患者65 ng/L(n=9280),急诊科患者215 ng/L(n=3706),其中6.07%(n=225)超过推荐正常上限。重症监护病房患者中39.02%(n=48,n=123)和内科住院患者中14.16%(n=67)超过推荐正常上限。作者认为临床 staff 在应用推荐正常上限诊断急性心肌梗死时需仔细解读hs-cTnI浓度,以避免在缺乏相应临床表现时误诊。
要点
- 全人群hs-cTnI第99百分位为296 ng/L,远高于厂商推荐正常上限40 ng/L。
- 5.4%(n=1080)的连续验血患者hs-cTnI超过40 ng/L。
- 排除急性心肌梗死及因临床原因申请检测者后,剩余18171例第99百分位为189 ng/L。
- 急诊科患者第99百分位为215 ng/L,6.07%(n=225)超过推荐正常上限。
- 重症监护病房患者39.02%(n=48,n=123)和内科住院患者14.16%(n=67)超过推荐正常上限。
适用人群与场景
- 2017年6月29日至2017年8月24日在南安普顿大学医院NHS基金会信托连续纳入的20000例因任何临床原因接受血液检查的住院和门诊患者。
- hs-cTnI在所有研究参与者中检测并嵌套分析,除非主管医生因临床原因已申请hs-cTnI检测。
研究设计与关键结果
- 研究类型为前瞻性观察性队列研究,纳入20000例连续住院和门诊患者,检测hs-cTnI浓度并分析第99百分位。
- 全人群hs-cTnI第99百分位为296 ng/L,厂商推荐正常上限为40 ng/L。
- 5.4%(n=1080)的全人群hs-cTnI超过40 ng/L。
- 排除诊断为急性心肌梗死者(n=122)和因临床原因申请hs-cTnI检测者(n=1707)后,剩余18171例第99百分位为189 ng/L。
- 住院患者第99百分位为563 ng/L(n=4759),门诊患者为65 ng/L(n=9280)。
- 急诊科患者第99百分位为215 ng/L(n=3706),其中6.07%(n=225)超过推荐正常上限。
- 重症监护病房患者39.02%(n=48,n=123)和内科住院患者14.16%(n=67)hs-cTnI超过推荐正常上限。
证据类型、等级与局限
- 证据类型为前瞻性观察性队列研究。
- 作者结论认为数据突出临床工作人员需仔细解读hs-cTnI浓度,尤其在应用推荐正常上限诊断急性心肌梗死时,以避免在缺乏适当临床表现时误诊。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为临床工作人员应仔细解读hs-cTnI浓度,尤其在应用推荐正常上限诊断急性心肌梗死时,以避免在缺乏适当临床表现时误诊。
- 数据显示全人群第99百分位(296 ng/L)远高于厂商推荐正常上限(40 ng/L),住院患者第99百分位(563 ng/L)高于门诊患者(65 ng/L),急诊科患者为215 ng/L;该信息适用于解读因任何临床原因验血患者的hs-cTnI结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the distribution, and specifically the true 99th centile, of high sensitivity cardiac troponin I (hs-cTnI) for a whole hospital population by applying the hs-cTnI assay currently used routinely at a large teaching hospital.
DESIGN: Prospective, observational cohort study.
SETTING: University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, between 29 June 2017 and 24 August 2017.
PARTICIPANTS: 20 000 consecutive inpatients and outpatients undergoing blood tests for any clinical reason. Hs-cTnI concentrations were measured in all study participants and nested for analysis except when the supervising doctor had requested hs-cTnI for clinical reasons.
MAIN OUTCOME MEASURES: Distribution of hs-cTnI concentrations of all study participants and specifically the 99th centile.
RESULTS: The 99th centile of hs-cTnI for the whole population was 296 ng/L compared with the manufacturer's quoted level of 40 ng/L (currently used clinically as the upper limit of normal; ULN). Hs-cTnI concentrations were greater than 40 ng/L in one in 20 (5.4%, n=1080) of the total population. After excluding participants diagnosed as having acute myocardial infarction (n=122) and those in whom hs-cTnI was requested for clinical reasons (n=1707), the 99th centile was 189 ng/L for the remainder (n=18 171). The 99th centile was 563 ng/L for inpatients (n=4759) and 65 ng/L for outpatients (n=9280). Patients from the emergency department (n=3706) had a 99th centile of 215 ng/L, with 6.07% (n=225) greater than the recommended ULN. 39.02% (n=48) of all patients from the critical care units (n=123) and 14.16% (n=67) of all medical inpatients had an hs-cTnI concentration greater than the recommended ULN.
CONCLUSIONS: Of 20 000 consecutive patients undergoing a blood test for any clinical reason at our hospital, one in 20 had an hs-cTnI greater than the recommended ULN. These data highlight the need for clinical staff to interpret hs-cTnI concentrations carefully, particularly when applying the recommended ULN to diagnose acute myocardial infarction, in order to avoid misdiagnosis in the absence of an appropriate clinical presentation.
TRIAL REGISTRATION: Clinicaltrials.gov NCT03047785.
参考来源
- Mariathas M, Allan R, Ramamoorthy S, et al. True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study. BMJ. 2019. PMID: 30867154. doi:10.1136/bmj.l729
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。